1-tert-butyl 3-ethyl 4-triflate-5,6-dihydropyridine-1,3(2H)-dicarboxylate | 170837-88-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: 1-tert-butyl 3-ethyl 4-triflate-5,6-dihydropyridine-1,3(2H)-dicarboxylate
• 英文别名: 1-tert-Butyl 3-ethyl 4-phenyl-5,6-dihydropyridin-1,3(2H)-dicarboxylate；1-(Tert-butyl) 3-ethyl 4-phenyl-5,6-dihydropyridine-1,3(2H)-dicarboxylate；1-O-tert-butyl 5-O-ethyl 4-phenyl-3,6-dihydro-2H-pyridine-1,5-dicarboxylate
• CAS: 170837-88-4
• 化学式: C₁₉H₂₅NO₄
• 分子量: 331.412
• InChiKey: PWNGZODWBPPGBE-UHFFFAOYSA-N

物化性质

• 沸点：
  437.2±45.0 °C(Predicted)
• 密度：
  1.133±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  24
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  55.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1-tert-butyl 3-ethyl 4-triflate-5,6-dihydropyridine-1,3(2H)-dicarboxylate 在 sodium cyanoborohydride 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 0.5h， 生成 ethyl 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine-3-carboxylate
  参考文献：
  名称：

  Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists

  摘要：

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

  DOI：

  10.1021/jm301774u
• 作为产物：
  描述：

  1-N-Boc-4-氧代-3-哌啶羧酸乙酯 在 四(三苯基膦)钯 、 sodium carbonate 、 二异丙胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 5.5h， 生成 1-tert-butyl 3-ethyl 4-triflate-5,6-dihydropyridine-1,3(2H)-dicarboxylate
  参考文献：
  名称：

  Structural Modifications to Tetrahydropyridine-3-carboxylate Esters en Route to the Discovery of M₅-Preferring Muscarinic Receptor Orthosteric Antagonists

  摘要：

  The M-5 muscarinic acetylcholine receptor is suggested to be a potential pharmacotherapeutic target for the treatment of drug abuse. We describe herein the discovery of a series of M-5-preferring orthosteric antagonists based on the scaffold of 1,2,5,6-tetrahydropyridine-3-carboxylic acid. Compound 56, the most selective compound in this series, possesses an 11-fold selectivity for the M-5 over M-1 receptor and shows little activity at M-2-M-4. This compound, although exhibiting modest affinity (K-i = 2.24 mu M) for the [H-3]N-methylscopolamine binding site on the M-5 receptor, is potent (IC50 = 0.45 nM) in inhibiting oxotremorine-evoked [H-3]DA release from rat striatal slices. Further, a homology model of human M-5 receptor based on the crystal structure of the rat M-3 receptor was constructed, and docking studies of compounds 28 and 56 were performed in an attempt to understand the possible binding mode of these novel analogues to the receptor.

  DOI：

  10.1021/jm301774u

文献信息

• Process for the preparation of enantiomerically enriched cyclic beta-aryl or heteroaryl carbocyclic acids
  申请人：Bachmann Stephan

  公开号：US20070232653A1

  公开（公告）日：2007-10-04

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.

  本发明涉及一种通过对下列方案进行对映选择性氢化反应，制备高对映异构体和对映选择性的顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法，其中X、Ar、n和m在此定义，并且包括相应的盐。
• BICYCLIC HETEROCYCLIC DERIVATIVE
  申请人：Nakahira Hiroyuki

  公开号：US20110190278A1

  公开（公告）日：2011-08-04

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R 1a is halogen, etc.; R 1m is H, etc.; G 1 is —N(R 1b )—, etc.; G 2 is —CO—, etc.; G 3 is —C(R 1c )(R 1d )—, etc.; G 4 is oxygen, etc.; R 1b is optionally substituted C 1-6 alkyl, etc.; R 1c and R 1d are independently the same or different, H, etc.; R 3 is H, optionally substituted C 1-6 alkyl, etc.; R 3a , R 3b , R 3 c and R 3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其可用作肾素抑制剂。[其中，R1a是卤素等；R1m是H等；G1是—N（R1b）—等；G2是—CO—等；G3是—C（R1c）（R1d）—等；G4是氧等；R1b是可选取代的C1-6烷基等；R1c和R1d独立选择为H等；R3是H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立选择为相同或不同的基团：-A-B（其中A是单键等，B是H等）等；n为1等。]
• PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYLCARBOCYCLIC ACIDS
  申请人：Bachmann Stephan

  公开号：US20110105758A1

  公开（公告）日：2011-05-05

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined hereinand corresponding salts thereof.

  本发明涉及一种通过对以下图示反应进行对映选择性氢化，以高对映异构体和对映选择性制备顺式取代的环状β-芳基或杂芳基羧酸衍生物的方法：其中X，Ar，n和m在此定义，并对应的盐。
• PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY ENRICHED CYCLIC BETA-ARYL OR HETEROARYL CARBOCYCLIC ACIDS
  申请人：Bachmann Stephan

  公开号：US20130253201A1

  公开（公告）日：2013-09-26

  The present invention relates to a process for the preparation of cis substituted cyclic β-aryl or heteroaryl carboxylic acid derivatives in high diastereo- and enantioselectivity by enantioselective hydrogenation in accordance with the following scheme wherein X, Ar, n, and m are defined herein and corresponding salts thereof.

  本发明涉及一种制备具有高对映选择性和高顺式取代的环状β-芳基或杂芳基羧酸衍生物的过程，通过根据以下方案进行对映选择性加氢，其中X，Ar，n和m在此定义，并且它们的相应盐。
• Bicyclic heterocyclic derivative
  申请人：Nakahira Hiroyuki

  公开号：US08389511B2

  公开（公告）日：2013-03-05

  The present invention relates to a compound of the following formula (I) or a pharmaceutically acceptable salt thereof, being useful as a renin inhibitor. [wherein R1a is halogen, etc.; R1m is H, etc.; G1 is —N(R1b)—, etc.; G2 is —CO—, etc.; G3 is —C(R1c)(R1d)—, etc.; G4 is oxygen, etc.; R1b is optionally substituted C1-6 alkyl, etc.; R1c and R1d are independently the same or different, H, etc.; R3 is H, optionally substituted C1-6 alkyl, etc.; R3a, R3b, R3c and R3d are independently the same or different, and a group: -A-B (said A is single bond, etc., and said B is H, etc.), etc.; and n is 1, etc.]

  本发明涉及以下式（I）的化合物或其药学上可接受的盐，其作为肾素抑制剂有用。[其中R1a为卤素等；R1m为H等；G1为—N（R1b）—等；G2为—CO—等；G3为—C（R1c）（R1d）—等；G4为氧等；R1b为可选取代的C1-6烷基等；R1c和R1d独立且相同或不同，为H等；R3为H、可选取代的C1-6烷基等；R3a、R3b、R3c和R3d独立且相同或不同，为-A-B基团（其中A为单键等，B为H等）等；n为1等。]